Method for reducing triptolide-induced hepatotoxicity based on ergothioneine
Through the combined treatment of ergothionine and triplothionine, an inflammatory animal model was established, and its effect of reducing triplothionine inducing hepatotoxicity was evaluated, forming a pharmaceutical composition, solving the problem of triplothionine hepatotoxicity and broadening ergothionine Because of its scope of application, it reduces the side effects of clinical medication.
Patent Information
- Application Number
- CN202411009310.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-12-06
AI Technical Summary
There is a problem of hepatotoxicity in clinical applications of threxine. The acquisition methods of existing drugs such as saffron and caper extracts are complex and the toxicological effects are unclear, resulting in limited clinical applications.
The combined treatment of ergothionine and triplothionine was used to evaluate the effect of ergothionine on triplothionine by establishing an inflammatory animal model, and through indicators such as liver coefficient and serum glutamic acid/glutamic acid level. It is judged to reduce the effect of triptyromethin inducing hepatotoxicity, and form a pharmaceutical composition at a mass ratio of 1-20:1.
Effectively reduce the hepatotoxicity induced by tributyrin, broaden the application range of ergothionein, reduce the side effects of clinical medication, provide new ideas for auxiliary medication for tributyrin, and ensure the safety of the drug.
Smart Images

Figure CN119074963A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of triptolide-induced hepatotoxicity alleviation, and in particular to an ergothioneine-based method for reducing triptolide-induced hepatotoxicity. Background Art
[0002] Triptolide (TP) is an epoxy diterpene lactone compound found in the roots, leaves, flowers and fruits of Tripterygium wilfordii Hook F, a plant of the Celastraceae family, and has strong anti-cancer and anti-inflammatory activities. Triptolide can inhibit the expression of cytokines such as TNF-α (tumor necrosis factor-α, a proinflammatory cytokine), IL-6 (interleukin-6, a proinflammatory cytokine), COX2 and IL-18, while inhibiting NF-κB, NLRP3, HMGB1, Atf6 / Chop, RANK / RANK / OPG, and Nrf2 signaling pathways to reduce cell adhesion and apoptosis, and play an anti-inflammatory role, but its specific mechanism remains unknown. Although triptolide has strong anti-inflammatory and anti-cancer activities, the numerous epoxy bridges in its structure determine that it must have strong toxicity.
[0003] However, given the various organ toxicities induced by triptolide, including the potential toxicity to various organs including the liver, kidney, ovary and heart, especially hepatotoxicity, its clinical application is greatly limited. Studies have found that TP-induced hepatotoxicity is associated with oxidative stress (ROS), which is caused by an imbalance between oxidation and antioxidants. ROS causes lipid and DNA damage, leading to organelle dysfunction and damage. A large number of in vivo and in vitro studies have found that TP can lead to an increase in ROS and malondialdehyde (MDA), and a decrease in superoxide dismutase (SOD), catalase (CAT), glutathione transferase (GST) and GSH (reduced glutathione, an important regulatory metabolite and antioxidant in cells).
[0004] Ergothioneine (EGT) is a natural histidine-derived compound with strong antioxidant activity. A large number of studies have confirmed that natural antioxidants have a positive effect on preventing liver diseases caused by oxidative stress. This is due to their ability to scavenge free radicals and enhance the activity of intracellular antioxidant enzymes. As an antioxidant, ergothioneine (EGT) can effectively eliminate hydroxyl radicals, chelate with ferrous and copper ions, inhibit the production of hydroxyl radicals by hydrogen peroxide, activate the natural antioxidant defense mechanism of cells, and can alleviate liver damage caused by oxidative stress. At physiological pH, ergothioneine (EGT) is stable because it mainly exists in the form of thiones, which makes it resistant to self-oxidation. Ergothioneine (EGT) can scavenge substances such as reactive oxygen and reactive nitrogen, thereby reducing oxidative stress.
[0005] In the prior art, the drugs used in combination with triptolide to reduce its toxicity include crocin, caper or caper extract, but these drugs are mainly obtained by plant extraction, are mixtures, and have unclear composition. Moreover, the efficacy and toxicological effects have not been fully clarified. The combination with triptolide may cause other symptoms, which is not conducive to the clinical application of triptolide.
[0006] To this end, a method for reducing triptolide-induced hepatotoxicity based on ergothioneine was designed to provide another technical solution to the above technical problems. Summary of the invention
[0007] The technical problem to be solved by the present invention is to provide a method for reducing the hepatotoxicity induced by triptolide based on ergothioneine, so as to solve the problems that other drugs for alleviating triptolide have high cost, low safety and insignificant effect.
[0008] In order to solve the above technical problems, the technical solution adopted by the present invention is:
[0009] A method for reducing triptolide-induced hepatotoxicity based on ergothioneine, comprising the following steps:
[0010] S1: Triptolide and ergothioneine were combined to treat the inflammatory animal model induced by sodium dextran sulfate; the effect of ergothioneine on the efficacy of triptolide was determined based on the disease activity index score, colon length, colon tissue pathological staining, colon tissue thioredoxin reductase activity, glutathione level, colon tissue thioredoxin system protein level and inflammatory factor expression level.
[0011] S2: The effect of ergothioneine on reducing triptolide-induced hepatotoxicity was determined based on the acute toxicity indicators of liver coefficient, serum glutamate / glutamate levels, and liver tissue pathological staining.
[0012] As a preferred embodiment of the method for reducing triptolide-induced hepatotoxicity based on ergothioneine provided by the present invention, in the step S1, an inflammatory animal model is established, and the steps are as follows:
[0013] The mice were fed with drinking water containing 3% DSS for 7 days, and triptolide and ergothioneine were administered to the mice by intraperitoneal injection. On the 8th day, the drinking water of the mice was replaced with sterile water, and an inflammatory animal model was obtained after fasting. The disease activity index, colon length, and colon tissue pathology of the mice were analyzed.
[0014] As a preferred embodiment of the method for reducing triptolide-induced hepatotoxicity based on ergothioneine provided by the present invention, in the step S1, colon tissue is extracted, and the steps are as follows:
[0015] Take colon tissue and place it in a centrifuge tube;
[0016] Add buffer PBS and enzyme inhibitor PMSF and homogenize;
[0017] The homogenized sample was centrifuged and the supernatant was collected.
[0018] As a preferred embodiment of the method for reducing triptolide-induced hepatotoxicity based on ergothioneine provided by the present invention, in the step S1, the protein concentration is determined as follows:
[0019] The protein solution was diluted with PBS, and samples were taken from each well and added to the ELISA plate. Subsequently, BCA working solution was added to each well. After incubation, the absorbance was detected, and the sample protein concentration was calculated according to the standard curve.
[0020] As a preferred embodiment of the method for reducing triptolide-induced hepatotoxicity based on ergothioneine provided by the present invention, in the step S1, the TrxR activity and GSH level of colon tissue are detected, and the steps are as follows:
[0021] A. Perform TrxR activity detection as follows:
[0022] After the protein concentration was determined, the samples were diluted to the same concentration with PBS buffer;
[0023] Add protein and NADPH to the ELISA plate;
[0024] After incubation at room temperature, TrxR activity in the control wells was specifically inhibited;
[0025] Then, a mixture of NADPH and DTNB was added, and the absorbance change was detected every 1 min within 5 min;
[0026] B. Perform GSH level test as follows:
[0027] Add protein to the ELISA plate, and set up 3 replicate wells and one control well for each protein sample;
[0028] NADPH and GR were added to the inside of the duplicate wells, and NADPH was added to the inside of the control wells;
[0029] After incubation at room temperature for 2 min, a mixture of NADPH and DTNB was added, and the absorbance change was detected within 5 min. The GSH level of the sample was equal to the slope of the sample well minus the slope of the control well.
[0030] As a preferred embodiment of the method for reducing triptolide-induced hepatotoxicity based on ergothioneine provided by the present invention, in the step S1, the Trx system protein level of colon tissue is detected, and the steps are as follows:
[0031] After the protein concentration is determined, the treated sample is diluted;
[0032] Place in a 100°C metal bath for reaction for 10 minutes;
[0033] After the reaction is completed, the sample is allowed to cool naturally and stored;
[0034] Western Blot technology was used to detect the protein levels of Trx system-related antioxidant enzymes.
[0035] As a preferred embodiment of the method for reducing triptolide-induced hepatotoxicity based on ergothioneine provided by the present invention, in the step S1, the level of inflammatory factors in colon tissue is detected, and the steps are as follows:
[0036] According to the standard operating procedures of the Trizol method, total RNA was extracted from colon tissue samples. The extracted RNA was reverse transcribed into cDNA using a two-step method, and the expression levels of inflammatory factors IL-1β, IL-6 and TNF-α were detected using real-time fluorescence quantitative PCR technology.
[0037] As a preferred embodiment of the method for reducing triptolide-induced hepatotoxicity based on ergothioneine provided by the present invention, in the step S2, the acute toxicity detection step for the liver is as follows:
[0038] Animal model establishment: mice were fed with drinking water containing 3% DSS for 7 days, and TP and EGT drugs were given to mice by intraperitoneal injection; after fasting for 12 hours on the 8th day, blood was collected from the eyeballs and liver tissue was extracted from the mice;
[0039] Hepatotoxicity analysis: After the liver was completely removed and cleaned, the liver weight was measured and the liver coefficient was calculated;
[0040] The extracted blood was allowed to stand at room temperature, and after the upper and lower layers were separated, it was centrifuged at a centrifugal force of 2500g and a temperature of 4°C for 15 minutes, and the supernatant was collected. The supernatant was diluted 20 times with physiological saline, and the AST and ALT levels in the serum were detected using a fully automatic biochemical analyzer. The mouse liver tissue was fixed with 4% paraformaldehyde and used for HE staining to observe the specific morphological structure and pathological damage of the cells.
[0041] The invention also discloses a pharmaceutical composition, comprising ergothioneine and triptolide, wherein the mass ratio of ergothioneine to triptolide is 1-20:1.
[0042] As a preferred embodiment of the pharmaceutical composition provided by the present invention, the pharmaceutical composition is used in the preparation of a drug for alleviating inflammatory diseases.
[0043] At the same time, through the above technical solutions, the present invention has at least the following beneficial effects:
[0044] (1) The present invention provides a method for reducing triptolide-induced hepatotoxicity based on ergothioneine, which can increase the use of ergothioneine by using ergothioneine in combination with triptolide, and at the same time alleviate the acute liver injury induced by triptolide in a specific disease model without affecting its efficacy; thereby providing a new idea for the auxiliary use of triptolide and reducing the side effects of clinical medication;
[0045] (2) When used, it not only broadens the application scope of EGT, but also alleviates TP-induced acute liver injury in diseased states without affecting the efficacy of TP, providing a new idea for the clinical auxiliary use of TP and opening up the application prospects of drugs that antagonize the hepatotoxicity of triptolide;
[0046] (3) Provide ergothioneine, a commonly used, well-researched, and low-cost clinical drug, to ensure its safety and reduce the risk of causing other symptoms. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying any creative work.
[0048] Figure 1 This is a schematic diagram of the evaluation of the results of the mouse colitis modeling of the present invention;
[0049] Figure 2 This is a schematic diagram of the colon HE staining results of the present invention;
[0050] Figure 3 This is a schematic diagram of the results of colon TrxR activity and GSH level of the present invention;
[0051] Figure 4 This is a schematic diagram of the protein expression level of the colon Trx system of the present invention;
[0052] Figure 5 It is a schematic diagram of the expression level of related pro-inflammatory factors in the colon of the present invention;
[0053] Figure 6 It is a schematic diagram of the acute toxicity evaluation results of the present invention. DETAILED DESCRIPTION
[0054] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0055] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings.
[0056] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features and technical solutions in the embodiments may be combined with each other.
[0057] It should be noted that similar reference numerals and letters denote similar items in the following drawings, and therefore, once an item is defined in one drawing, further definition and explanation thereof is not required in subsequent drawings.
[0058] Embodiment 1:
[0059] Reference Figure 1-Figure 6 , an ergothioneine-based approach to reduce triptolide-induced hepatotoxicity.
[0060] 1. Effect of ergothioneine on the efficacy of TP in the treatment of colitis
[0061] 1.1. Animal model establishment
[0062] Twenty-four male C57BL / 6J mice that met the body weight requirements were randomly divided into four groups, namely, the control group, the DSS (dextran sulfate sodium salt) group, the TP group and the TP+EGT group.
[0063] The experimental animals were treated for 7 days. The specific treatment methods are shown in the table below. The mice were weighed daily, the feces and blood in the stool were observed, and their survival was recorded. Blood was collected from the eyeballs after fasting for 12 hours for subsequent analysis, which can be referred to Table 1.
[0064] Table 1: Treatment methods of experimental animals in each group
[0065]
[0066] 1.2. Disease activity index scoring of mice
[0067] In order to comprehensively analyze the pathological conditions of mice, the survival status of mice was systematically observed every day from the day of administration. The disease activity index (DAI) of mice was scored, and the severity of the disease in mice was comprehensively reflected by comprehensively considering the weight loss score, fecal trait score, and fecal blood score of mice, as shown in Table 2.
[0068] Table 2: DAI scoring criteria
[0069]
[0070]
[0071] 1.3. Colon length observation
[0072] The complete colon tissue of each mouse was carefully isolated and its length was accurately measured to further evaluate the degree of intestinal inflammation. Finally, the colon length data obtained were statistically analyzed.
[0073] 1.4. Colon pathological histological observation
[0074] The colon samples were fixed in 4% paraformaldehyde solution and used for HE staining to observe the specific morphological structure and pathological damage of the cells. The colon tissue sections and HE staining were completed by Chengdu Lilai Medical Experimental Center.
[0075] 1.5. Colon tissue extraction and protein concentration determination
[0076] (1) Processing of colon tissue. The specific steps are as follows:
[0077] ① Sample collection: About 50 mg of colon tissue was placed in a 1.5 mL centrifuge tube.
[0078] ② Add samples. Add 500 μL of PBS (PH 7.4) buffer and 5 μL of 100 mM enzyme inhibitor PMSF to each sample.
[0079] ③ Homogenize. Homogenize at 60 Hz for 120 seconds. The homogenization time can be appropriately increased according to the sample conditions.
[0080] ④ Centrifuge. Centrifuge at 4℃, 12000rpm for 10min. ⑤ Storage. Take the supernatant and store at -80℃.
[0081] (2) Determination of protein concentration
[0082] The protein concentration was determined by the BCA method. The BCA kit was provided by Sangon Bioprocess Co., Ltd. The specific method is as follows:
[0083] After the protein solution was diluted 10 times with PBS (PH 7.4), 5 μl was taken from each well and added to the ELISA plate. Three parallel wells were set for each protein sample.
[0084] Then, 200 μl of BCA working solution (solution A: solution B = 50:1) was added to each well, and the absorbance was detected at 562 nm after incubation at 37° C. for 30 min, and the sample protein concentration was calculated according to the standard curve.
[0085] 1.6. Detection of TrxR activity and GSH levels in colon tissue
[0086] Determine the sample protein concentration as in step 1.5. After treatment, dilute the sample to the same concentration using PBS buffer to ensure the reliability of subsequent experimental results.
[0087] (1) Thioredoxin reductase (TrxR) activity detection
[0088] 25 μg protein and 100 μM NADPH were added to the ELISA plate (three replicate wells and one control well were set for each protein sample). After incubation at room temperature for 2 min, 300 nM ATG was added to the control well to specifically inhibit TrxR activity. After incubation at room temperature for 5 min, a mixture of 100 μM NADPH and 2 mM DTNB was added to each well, and the absorbance change at 412 nm every 1 min within 5 min was immediately detected. TrxR activity was equal to the slope of the sample well minus the slope of the control well.
[0089] (2) Glutathione (GSH) level detection
[0090] 10 μg protein (three replicate wells and one control well were set for each protein sample), 100 μM NADPH and 50 nM GR were added to the ELISA plate, and no GR was added to the control well. After incubation at room temperature for 5 min, a mixture of 100 μM NADPH and 2 mM DTNB was added to each well, and the absorbance change at 412 nm was immediately detected every 1 min within 5 min. The sample GSH level was equal to the slope of the sample well minus the slope of the control well.
[0091] 1.7. Detection of Trx system protein levels in colon tissue
[0092] Determine the sample protein concentration according to the steps in Experimental Method 5. And process the sample according to the following steps:
[0093] ① Sample dilution: After treatment, add 40 μL of 5× loading buffer (reduced form, containing DTT) and an appropriate amount of PBS buffer for dilution.
[0094] ② Denaturation: After adding the sample, place it in a 100℃ metal bath for reaction for 10 minutes. The purpose of this step is to completely denature the protein.
[0095] ③ Storage. After the reaction is completed, let the sample cool naturally and store it at -20℃ for subsequent use.
[0096] Western Blot technology was used to detect the protein levels of Trx system-related antioxidant enzymes. In the experiment, antibodies with different dilution ratios were used to ensure the sensitivity and specificity of the detection. The specific antibody dilution ratios are as follows: Trx1 is 1:1000; Trx2 is 1:1000; TrxR1 is 1:3000; TrxR2 is 1:2000; Prx1 is 1:3000; Prx2 is 1:3000; Prx3 is 1:3000; GAPDH is 1:5000; goat anti-rabbit is 1:5000; goat anti-mouse is 1:5000.
[0097] Among them, Trx1: thioredoxin-1, is an important regulator of cellular redox homeostasis, with antioxidant effect; Trx2: thioredoxin-2, is an important regulator of cellular redox homeostasis, with antioxidant effect; TrxR1: thioredoxin reductase-1, is an important member of the intracellular antioxidant thiol reduction buffer system, and is an antioxidant enzyme; TrxR2: thioredoxin reductase-2, is an important member of the intracellular antioxidant thiol reduction buffer system, and is an antioxidant enzyme; Prx1: peroxidase-1, an antioxidant enzyme that can decompose harmful hydrogen peroxide in cells; Prx2 : Peroxidase-2, an antioxidant enzyme that can decompose harmful hydrogen peroxide in cells; Prx3: Peroxidase-3, an antioxidant enzyme that can decompose harmful hydrogen peroxide in cells; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase, which is highly expressed in almost all tissues, and its expression level is generally constant in the same cells / tissues, and is not affected by some recognition sites contained and remains constant, so it is widely used in WB; WB: Protein immunoblotting, is a technique in which proteins are transferred to a membrane after electrophoresis separation, and then detected using antibodies, which can semi-quantitatively detect the expression rate of proteins.
[0098] The gray value of the protein band was calculated by Image J software, and the relative protein expression was calculated with GAPDH as the internal reference. Finally, the experimental data were analyzed by GraphPad Prism 9.4.0 software.
[0099] 1.8. Detection of inflammatory factors in colon tissue
[0100] (1) Sample processing. Take about 50 mg of colon tissue and wash it thoroughly with physiological saline to remove the contents. After washing, place it in a 1.5 mL enzyme-free centrifuge tube.
[0101] (2) Total RNA extraction: Total RNA was extracted from colon tissue samples according to the standard operating procedure of the Trizol method. This method can effectively and efficiently separate RNA from animal tissues with high quality.
[0102] (3) RNA reverse transcription: The extracted RNA is reverse transcribed into cDNA using a two-step method.
[0103] (4) Detection of inflammatory factor gene levels. Real-time fluorescence quantitative PCR technology was used to detect the expression levels of inflammatory factors IL-1β, IL-6, and TNF-α.
[0104] In order to eliminate the possible differences between samples during reverse transcription and RT-qPCR, a specific method is used in data analysis. Specifically, the content ratio of the target gene and the internal reference gene is used as an indicator to evaluate the expression level of the target gene. This method can effectively reduce individual differences between samples and ensure the accuracy and reliability of the results.
[0105] 2. Effects of ergothioneine on TP hepatotoxicity
[0106] 2.1. Acute hepatotoxicity evaluation
[0107] (1) Calculation of liver coefficient. After complete resection, the liver was thoroughly washed with saline to remove all blood and other impurities. The liver was weighed, the liver coefficient was calculated, and statistical analysis was performed.
[0108] (2) Pathological histological observation. The liver was removed from the same position, washed with saline, fixed with 4% paraformaldehyde for 24 hours, and then sent to Chengdu Lilai Medical Experimental Center for hematoxylin and eosin (H&E) staining. The main observations were whether the morphology of hepatocytes and liver lobules was intact; the degeneration, arrangement and necrosis of hepatocytes; the infiltration of inflammatory cells in various parts of the liver; and the hyperplasia of liver fibrosis.
[0109] (3) AST and ALT level detection. After blood extraction, place at room temperature for 4-5 hours, separate into layers and centrifuge at 4°C and 2500 rpm for 15 minutes. Collect the supernatant and dilute it 20 times with saline. Then use an automatic biochemical analyzer to detect the AST and ALT levels in the serum. Store the remaining samples at -80°C for later use.
[0110] Among them, ALT: alanine aminotransferase, is an enzyme in the human body, and its value is often considered to be an indicator of liver function; AST: aspartate aminotransferase, is an enzyme in the human body, and its value is often considered to be an indicator of liver function.
[0111] 3. Effect of ergothioneine on the efficacy of TP in the treatment of colitis
[0112] 3.1. Evaluation of colitis model
[0113] Evaluation of colitis damage in mice: DAI score and colon length. Figure 1B) shows that there is a significant difference in the colon length between the control group (Control) and the modeling group (DSS). At the same time, the DAI score of mice ( Figure 1 A) shows that the score of the model group is higher than that of the control group (Control), that is, the inflammatory animal model was successfully established by feeding mice with drinking water containing 3% DSS. At the same time, the colon length ( Figure 1 B) showed that EGT had no significant antagonistic effect on TP.
[0114] 3.2. Colon histopathological evaluation
[0115] (1) Control group. The colon mucosal epithelial layer remained intact, and the infiltration of inflammatory cells in the mucosal layer and submucosal layer was minimal, indicating a mild inflammatory reaction. The intestinal glands in the lamina propria were stable in morphology and orderly arranged, with no abnormalities.
[0116] (2) DSS group. The colon mucosal epithelial layer was obviously damaged, accompanied by erosion. At the same time, a large number of inflammatory cells infiltrated the mucosal layer and submucosal layer, indicating a severe inflammatory reaction. The intestinal glands in the lamina propria were deformed and disordered, showing obvious pathological changes.
[0117] (3) Mice in the TP group and TP+EGT group. The colon mucosal epithelial layer was relatively intact, with no obvious erosion. There was less inflammatory cell infiltration in the mucosal layer and submucosal layer, indicating that the inflammatory response was under control to a certain extent. The intestinal glands in the lamina propria were stable in morphology and arranged neatly, similar to those in the control group. In addition, there were no significant differences between the TP group and the TP+EGT group in terms of colon damage and stability of intestinal gland arrangement.
[0118] In summary, it is speculated that both TP alone and TP combined with EGT can alleviate colonic mucosal injury and inflammatory response in DSS-induced acute ulcerative colitis, and there is no significant difference in the colon protective effect between the two.
[0119] 3.3. Detection of TrxR activity and GSH levels in colon tissue
[0120] TP can treat DSS-induced colitis in mice. In order to explore whether the combined use of EGT would affect the effect of TP in treating colitis and whether the mechanism of TP in improving colitis is related to TrxR activity or GSH level, the relevant indicators of colon tissue were detected to evaluate the antioxidant function of Trx and Grx system. Figure 3 The results showed that 0.6 mg / kg TP could enhance colon TrxR activity, while when 0.6 mg / kg TP was used in combination with 2 mg / kg EGT, there was almost no change in the effect on colon TrxR activity and GSH levels, indicating that TP can effectively improve the level of oxidative stress in the body, and the combined use of EGT has no effect on TP.
[0121] 3.4. Determination of protein content in colonic tissue
[0122] In order to further explore whether the combined use of EGT has an effect on the treatment of colitis with TP, the protein levels of antioxidant enzymes related to the Trx system were detected. Figure 4 As shown. Giving 0.6mg / kg TP alone to colitis mice led to an up-regulation trend in the expression of Trx system-related antioxidant proteins under oxidative stress, inducing up-regulation of the expression of related antioxidant proteins such as Trx1 and Prx1 / 2 / 3, and the body's thiol-dependent antioxidant system exerted an antioxidant effect. When 0.6mg / kg TP was used in combination with 2mg / kg EGT, there was almost no effect on the antioxidant function of TP.
[0123] 3.5. Inflammatory factor detection results
[0124] In order to explore the mechanism of EGT combined with TP in reducing colitis inflammation, related pro-inflammatory factors were detected. Figure 5 As shown. At the beginning of inflammation, neutrophils and macrophages infiltrate the intestinal mucosa of the IBD site and release a large amount of ROS and proinflammatory factors, including IL-6, IL-1β and TNF-α. Excessive production of ROS can lead to oxidative damage to DNA, proteins and lipids, further promoting the initiation and progression of UC. When 0.6mg / kg TP was used in combination with 2mg / kg EGT, the proinflammatory factors IL-6 and IL-1β decreased significantly, and the proinflammatory factor TNF-α also showed a downward trend. The two had similar effects in reducing the levels of inflammatory factors and had almost no effect on the anti-inflammatory function of TP.
[0125] 4. Effects of ergothioneine on TP hepatotoxicity
[0126] 4.1 Acute toxicity evaluation results
[0127] refer to Figure 6 , among which, (A) serum ALT and AST levels; (B) liver tissue HE staining (HE staining is hematoxylin-eosin staining, one of the commonly used staining methods, used to observe the specific morphological structure of cells); (C) liver coefficient. TP and EGT were administered to mice in combination to observe whether EGT could improve TP-induced hepatotoxicity.
[0128] The levels of AST and ALT in mouse serum showed ( Figure 6 A), 0.6 mg / kg TP can significantly induce liver damage in mice, while the combined administration of 2 mg / kg EGT and 0.6 mg / kg TP can significantly reduce serum AST and ALT levels.
[0129] Mouse HE staining sections ( Figure 6B) It also confirmed that the degree of liver tissue damage in mice in the group co-administered with 2 mg / kg EGT and 0.6 mg / kg TP was lower, indicating that the combination of EGT and TP can significantly improve TP-induced acute hepatotoxicity.
[0130] The results of liver coefficient showed that the TP group decreased significantly compared with the control group and DSS group; the liver coefficient increased significantly when EGT was used in combination with TP compared with TP alone, approaching the DSS group and control group; compared with the control group mice, the liver coefficient of the DSS group mice decreased significantly, which may be because the DSS group had severe colitis, which caused an overall reaction of the body and affected the liver to a certain extent, but its effect on the liver was much less than that of the TP group.
[0131] The present invention can also be implemented by the following alternatives:
[0132] 1. The same effect of reducing triptolide-induced hepatotoxicity can be achieved by changing the concentration of EGT combined with triptolide.
[0133] 2. The same effect of reducing triptolide-induced hepatotoxicity can be achieved by changing the model construction method. For example, in this embodiment, male C57BL / 6J mice are given TP and EGT at the same time, and a colitis model is constructed for seven days. In other embodiments:
[0134] ① It may be changed to add EGT in advance, and then add TP when constructing the UC model.
[0135] ② Alternatively, TP can be given for a few days first, followed by EGT for a few days. Both may have the same effect of alleviating triptolide-induced hepatotoxicity.
[0136] ④ Instead of using male C57BL / 6J mice, it is possible to change the animal strain, gender, and age
[0137] ⑤ It is possible that EGT can be combined with triptolide to reduce its triptolide-induced hepatotoxicity through cell / bacterial / microbial models instead of animal models.
[0138] 3. The same purpose can be achieved by changing the test items. For example, in this embodiment, HE staining results, liver coefficient, AST, ALT, TrxR activity, and Trx system-related protein levels are tested to prove that EGT can reduce TP-induced hepatotoxicity without affecting its anti-colitis efficacy. In other embodiments, other redox pathways in the body or other mechanisms such as CYP450, P-gp, autophagy, apoptosis, metabolic disorders, immune system, intestinal flora, etc. are detected to prove that EGT combined with triptolide can reduce triptolide-induced hepatotoxicity.
[0139] 4. The same effect can be exerted by changing the specific disease type. For example, the colitis model constructed in this embodiment can be used for treatment by constructing models such as rheumatoid arthritis. Since TP is highly toxic, EGT can be used in combination to reduce the hepatotoxicity induced by triptolide.
[0140] Embodiment 2:
[0141] Based on the above embodiment 1, a pharmaceutical composition is disclosed, comprising ergothioneine and triptolide, wherein the mass ratio of ergothioneine to triptolide is 1-20:1.
[0142] Embodiment three:
[0143] Based on the above Example 2, the use of the pharmaceutical composition in preparing a drug for alleviating inflammatory diseases is disclosed.
[0144] The preferred embodiments of the present invention disclosed above are only used to help explain the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the present invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.
Claims
1. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine, characterized in that, Here are the steps: S1: Triptolide and ergothioneine were combined to treat the inflammatory animal model induced by sodium dextran sulfate; the effect of ergothioneine on the efficacy of triptolide was determined based on the disease activity index score, colon length, colon tissue pathological staining, colon tissue thioredoxin reductase activity, glutathione level, colon tissue thioredoxin system protein level and inflammatory factor expression level. S2: The effect of ergothioneine on reducing triptolide-induced hepatotoxicity was determined based on the acute toxicity indicators of liver coefficient, serum glutamate / glutamate levels, and liver tissue pathological staining.
2. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine according to claim 1, characterized in that, In step S1, an inflammatory animal model is established, and the steps are as follows: The mice were fed with drinking water containing 3% DSS for 7 days, and triptolide and ergothioneine were administered to the mice by intraperitoneal injection. On the 8th day, the drinking water of the mice was replaced with sterile water, and an inflammatory animal model was obtained after fasting. The disease activity index, colon length, and colon tissue pathology of the mice were analyzed.
3. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine according to claim 1, characterized in that, In step S1, colon tissue is extracted, and the steps are as follows: Take colon tissue and place it in a centrifuge tube; Add buffer PBS and enzyme inhibitor PMSF and homogenize; The homogenized sample was centrifuged and the supernatant was collected.
4. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine according to claim 1, characterized in that, In step S1, the protein concentration is determined as follows: The protein solution was diluted with PBS, and samples were taken from each well and added to the ELISA plate. Subsequently, BCA working solution was added to each well. After incubation, the absorbance was detected, and the sample protein concentration was calculated according to the standard curve.
5. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine according to claim 2, characterized in that, In step S1, the TrxR activity and GSH level of colon tissue are detected as follows: A. Perform TrxR activity detection as follows: After the protein concentration was determined, the samples were diluted to the same concentration with PBS buffer; Add protein and NADPH to the ELISA plate; After incubation at room temperature, TrxR activity in the control wells was specifically inhibited; Then, a mixture of NADPH and DTNB was added, and the absorbance change was detected every 1 min within 5 min; B. Perform GSH level test as follows: Add protein to the ELISA plate, and set up 3 replicate wells and one control well for each protein sample; NADPH and GR were added to the inside of the duplicate wells, and NADPH was added to the inside of the control wells; After incubation at room temperature for 2 min, a mixture of NADPH and DTNB was added, and the absorbance change was detected within 5 min. The GSH level of the sample was equal to the slope of the sample well minus the slope of the control well.
6. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine according to claim 2, characterized in that, In step S1, the Trx system protein level in colon tissue is detected in the following steps: After the protein concentration is determined, the treated sample is diluted; Place in a 100°C metal bath for reaction for 10 minutes; After the reaction is completed, the sample is allowed to cool naturally and stored; Western Blot technology was used to detect the protein levels of Trx system-related antioxidant enzymes.
7. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine according to claim 1, characterized in that, In step S1, the level of inflammatory factors in colon tissue is detected, and the steps are as follows: According to the standard operating procedures of the Trizol method, total RNA was extracted from colon tissue samples. The extracted RNA was reverse transcribed into cDNA using a two-step method, and the expression levels of inflammatory factors IL-1β, IL-6 and TNF-α were detected using real-time fluorescence quantitative PCR technology.
8. A method for reducing triptolide-induced hepatotoxicity based on ergothioneine according to claim 1, characterized in that, In step S2, the acute toxicity test for the liver is as follows: Animal model establishment: mice were fed with drinking water containing 3% DSS for 7 days, and TP and EGT drugs were given to mice by intraperitoneal injection; after fasting for 12 hours on the 8th day, blood was collected from the eyeballs and liver tissue was extracted from the mice; Hepatotoxicity analysis: After the liver was completely removed and cleaned, the liver weight was measured and the liver coefficient was calculated; The extracted blood was allowed to stand at room temperature, and after the upper and lower layers were separated, it was centrifuged at a centrifugal force of 2500g and a temperature of 4°C for 15 minutes, and the supernatant was collected. The supernatant was diluted 20 times with physiological saline, and the AST and ALT levels in the serum were detected using a fully automatic biochemical analyzer. The mouse liver tissue was fixed with 4% paraformaldehyde and used for HE staining to observe the specific morphological structure and pathological damage of the cells.
9. A pharmaceutical composition comprising ergothioneine and triptolide, characterized in that: The mass ratio of ergothioneine to triptolide is 1-20:
1.
10. Use of the pharmaceutical composition according to claim 9 in the preparation of a drug for alleviating inflammatory diseases.
